Currently, finding an effective treatment for primary membranous nephropathy is a major challenge for modern nephrologists. Consequently, clinicians constantly seek therapies that minimize toxic side effects while maximizing long-term remission. Recently, the landmark MAJESTY phase 3 trial compared the efficacy of obinutuzumab against tacrolimus. Therefore, this study represents a major shift in the management of this complex autoimmune kidney disease.
Comparing Treatments for Primary Membranous Nephropathy
Historically, physicians used traditional immunosuppressants like tacrolimus to induce disease remission. However, these oral medications often cause significant nephrotoxicity and other severe adverse effects. To address this, researchers designed the phase 3 MAJESTY clinical trial. Specifically, they randomized 142 adult patients with primary membranous nephropathy into two distinct treatment groups. In this trial, the first group received intravenous obinutuzumab, while the second group took oral tacrolimus.
Impressive Remission Rates at Week 104
Ultimately, the primary endpoint of the trial was complete remission at week 104. Additionally, researchers defined complete remission as a low urinary protein-to-creatinine ratio and stable kidney function. Indeed, at the end of the study, 37% of patients in the obinutuzumab group achieved complete remission. In contrast, only 6% of patients in the tacrolimus group achieved this status. Consequently, the trial demonstrated a massive 31 percentage point adjusted difference in favor of obinutuzumab. Furthermore, the monoclonal antibody showed consistent benefits across all prespecified patient subgroups.
Evaluating Safety and Tolerability Profiles
Obviously, safety represents another critical factor when choosing a therapy for kidney disease. Fortunately, the two treatment groups exhibited comparable safety profiles throughout the study. Specifically, serious adverse events occurred in 22% of the obinutuzumab group and 19% of the tacrolimus group. Moreover, both cohorts experienced highly similar rates of infections. However, more patients in the tacrolimus group discontinued treatment due to adverse events. Therefore, obinutuzumab offers a more tolerable therapeutic option for long-term management.
Frequently Asked Questions
Q1: What is the primary advantage of obinutuzumab over tacrolimus?
Specifically, obinutuzumab achieves significantly higher complete remission rates at week 104 compared to tacrolimus with comparable safety.
Q2: How was complete remission defined in the MAJESTY trial?
Indeed, the trial defined complete remission as a low urinary protein-to-creatinine ratio with stable kidney function.
Q3: Did the study identify any new safety concerns for obinutuzumab?
Importantly, the trial did not identify new safety signals, and both treatment groups showed similar adverse event rates.
References
- Fervenza FC et al. Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy. N Engl J Med. 2026 Jun 05. doi: 10.1056/NEJMoa2602678. PMID: 42246654.
- MedPage Today. B-Cell Depleter Nabs Phase III Win in Autoimmune Kidney Disease. Published June 05, 2026.
- FirstWord Pharma. Roche shares more details on Gazyva’s autoimmune kidney disease win. Published June 05, 2026.